BioMarin Pharmaceutical (BMRN) Competitors $57.29 -1.08 (-1.85%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$57.74 +0.45 (+0.79%) As of 07/18/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BMRN vs. ALNY, BIIB, UTHR, INCY, NBIX, EXEL, EXAS, RGEN, HALO, and IONSShould you be buying BioMarin Pharmaceutical stock or one of its competitors? The main competitors of BioMarin Pharmaceutical include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), Exelixis (EXEL), Exact Sciences (EXAS), Repligen (RGEN), Halozyme Therapeutics (HALO), and Ionis Pharmaceuticals (IONS). These companies are all part of the "biotechnology" industry. BioMarin Pharmaceutical vs. Its Competitors Alnylam Pharmaceuticals Biogen United Therapeutics Incyte Neurocrine Biosciences Exelixis Exact Sciences Repligen Halozyme Therapeutics Ionis Pharmaceuticals BioMarin Pharmaceutical (NASDAQ:BMRN) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations. Do institutionals and insiders believe in BMRN or ALNY? 98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 0.9% of BioMarin Pharmaceutical shares are owned by company insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has higher earnings & valuation, BMRN or ALNY? BioMarin Pharmaceutical has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioMarin Pharmaceutical$2.85B3.85$426.86M$2.6921.30Alnylam Pharmaceuticals$2.25B18.59-$278.16M-$2.09-153.36 Does the media refer more to BMRN or ALNY? In the previous week, Alnylam Pharmaceuticals had 17 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 32 mentions for Alnylam Pharmaceuticals and 15 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 1.13 beat Alnylam Pharmaceuticals' score of 0.75 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 9 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 11 Very Positive mention(s) 5 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Is BMRN or ALNY more profitable? BioMarin Pharmaceutical has a net margin of 17.76% compared to Alnylam Pharmaceuticals' net margin of -11.49%. BioMarin Pharmaceutical's return on equity of 11.34% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets BioMarin Pharmaceutical17.76% 11.34% 8.95% Alnylam Pharmaceuticals -11.49%-510.31%-6.48% Do analysts recommend BMRN or ALNY? BioMarin Pharmaceutical currently has a consensus target price of $93.78, indicating a potential upside of 63.70%. Alnylam Pharmaceuticals has a consensus target price of $346.13, indicating a potential upside of 7.99%. Given BioMarin Pharmaceutical's higher possible upside, equities analysts clearly believe BioMarin Pharmaceutical is more favorable than Alnylam Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioMarin Pharmaceutical 0 Sell rating(s) 6 Hold rating(s) 18 Buy rating(s) 0 Strong Buy rating(s) 2.75Alnylam Pharmaceuticals 1 Sell rating(s) 3 Hold rating(s) 21 Buy rating(s) 0 Strong Buy rating(s) 2.80 Which has more volatility & risk, BMRN or ALNY? BioMarin Pharmaceutical has a beta of 0.17, meaning that its share price is 83% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500. SummaryBioMarin Pharmaceutical beats Alnylam Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get BioMarin Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BMRN vs. The Competition Export to ExcelMetricBioMarin PharmaceuticalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.19B$2.95B$5.55B$9.40BDividend YieldN/A2.47%3.75%4.03%P/E Ratio21.3019.7528.0119.82Price / Sales3.85300.24432.8198.20Price / Cash17.9842.5936.1658.27Price / Book1.937.678.125.65Net Income$426.86M-$55.28M$3.25B$257.91M7 Day Performance-1.39%4.85%1.68%3.38%1 Month Performance3.71%11.70%7.30%11.11%1 Year Performance-31.87%3.69%32.89%18.99% BioMarin Pharmaceutical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BMRNBioMarin Pharmaceutical4.9888 of 5 stars$57.29-1.9%$93.78+63.7%-31.3%$11.19B$2.85B21.303,040News CoveragePositive NewsAnalyst ForecastAnalyst RevisionALNYAlnylam Pharmaceuticals4.0395 of 5 stars$324.13-2.3%$341.91+5.5%+35.4%$42.26B$2.25B-155.092,230News CoverageAnalyst ForecastAnalyst RevisionBIIBBiogen4.9139 of 5 stars$130.13-2.1%$188.48+44.8%-44.5%$19.07B$9.68B12.857,605Trending NewsInsider TradeAnalyst RevisionUTHRUnited Therapeutics4.9873 of 5 stars$290.39-1.4%$386.15+33.0%-11.2%$13.10B$2.88B11.591,305Positive NewsINCYIncyte4.5517 of 5 stars$67.27-1.7%$74.53+10.8%+3.8%$13.02B$4.24B210.232,617Insider TradeAnalyst RevisionNBIXNeurocrine Biosciences4.4722 of 5 stars$127.88-1.0%$162.00+26.7%-8.4%$12.66B$2.36B43.351,800Trending NewsAnalyst RevisionEXELExelixis4.8218 of 5 stars$44.16-4.3%$43.56-1.4%+97.1%$12.04B$2.17B20.071,147Positive NewsAnalyst ForecastEXASExact Sciences4.6805 of 5 stars$52.48-1.6%$70.40+34.1%+6.1%$9.90B$2.76B-9.527,000RGENRepligen4.6354 of 5 stars$124.43-2.4%$172.83+38.9%-8.9%$6.99B$634.44M-276.511,778News CoverageAnalyst RevisionHALOHalozyme Therapeutics4.9603 of 5 stars$54.22+0.4%$61.90+14.2%+4.0%$6.68B$1.02B14.42390Positive NewsAnalyst ForecastIONSIonis Pharmaceuticals4.4693 of 5 stars$41.78-2.8%$58.25+39.4%-11.8%$6.65B$705M-13.971,069 Related Companies and Tools Related Companies ALNY Competitors BIIB Competitors UTHR Competitors INCY Competitors NBIX Competitors EXEL Competitors EXAS Competitors RGEN Competitors HALO Competitors IONS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BMRN) was last updated on 7/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioMarin Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BMRN Stock Alerts